The Europe High Intensity Focused Ultrasound Market would witness market growth of 6.8% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe High Intensity Focused Ultrasound Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $122.2 million by 2031. The UK market is experiencing a CAGR of 5.8% during 2024-2031. Additionally, the France market would exhibit a CAGR of 7.7% during 2024-2031.
HIFU provides a non-surgical solution for managing uterine fibroids. By targeting fibroid tissues with focused ultrasound, HIFU induces necrosis and shrinkage of fibroids, reducing symptoms such as heavy menstrual bleeding and pelvic pain. HIFU is used to treat endometriosis by targeting and ablating endometrial lesions. This application offers a minimally invasive alternative to traditional surgical treatments for endometriosis.
Also, in pain management, HIFU treats chronic pain conditions such as back pain and arthritis. By targeting nerve tissues or pain-generating structures with focused ultrasound, HIFU can relieve pain and improve the quality of life for patients suffering from chronic pain conditions. HIFU can be employed in pain management for localized nerve ablation, targeting specific nerves responsible for chronic pain and providing long-lasting relief.
The increasing cases of breast cancer across Europe drive the adoption of HIFU technology in various countries. This trend encourages the development of specialized HIFU clinics and integration into existing healthcare systems across the continent. As breast cancer rates rise, European countries may prioritize innovative treatments like HIFU in national healthcare policies and cancer treatment guidelines, potentially leading to better coverage and reimbursement. According to the European Commission, 374,800 women are estimated to be diagnosed with breast cancer in 2022. 95,800 women are estimated to die of breast cancer in 2022. Increased breast cancer cases stimulate more clinical trials and studies within Europe to explore the efficacy of HIFU in treating breast cancer, leading to improved clinical evidence and validation. Thus, the increasing number of breast cancer cases in the region is driving the growth of the market.
The Germany market dominated the Europe High Intensity Focused Ultrasound Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $122.2 million by 2031. The UK market is experiencing a CAGR of 5.8% during 2024-2031. Additionally, the France market would exhibit a CAGR of 7.7% during 2024-2031.
HIFU provides a non-surgical solution for managing uterine fibroids. By targeting fibroid tissues with focused ultrasound, HIFU induces necrosis and shrinkage of fibroids, reducing symptoms such as heavy menstrual bleeding and pelvic pain. HIFU is used to treat endometriosis by targeting and ablating endometrial lesions. This application offers a minimally invasive alternative to traditional surgical treatments for endometriosis.
Also, in pain management, HIFU treats chronic pain conditions such as back pain and arthritis. By targeting nerve tissues or pain-generating structures with focused ultrasound, HIFU can relieve pain and improve the quality of life for patients suffering from chronic pain conditions. HIFU can be employed in pain management for localized nerve ablation, targeting specific nerves responsible for chronic pain and providing long-lasting relief.
The increasing cases of breast cancer across Europe drive the adoption of HIFU technology in various countries. This trend encourages the development of specialized HIFU clinics and integration into existing healthcare systems across the continent. As breast cancer rates rise, European countries may prioritize innovative treatments like HIFU in national healthcare policies and cancer treatment guidelines, potentially leading to better coverage and reimbursement. According to the European Commission, 374,800 women are estimated to be diagnosed with breast cancer in 2022. 95,800 women are estimated to die of breast cancer in 2022. Increased breast cancer cases stimulate more clinical trials and studies within Europe to explore the efficacy of HIFU in treating breast cancer, leading to improved clinical evidence and validation. Thus, the increasing number of breast cancer cases in the region is driving the growth of the market.
List of Key Companies Profiled
- EDAP TMS S.A
- Sonablate Corp.
- Verasonics, Inc.
- ALPINION MEDICAL SYSTEMS Co., Ltd.
- Theraclion
- Lynton Lasers Ltd
- ULTRAISER
- PROFOUND MEDICAL CORP.
Market Report Segmentation
By End Use
- Hospital
- Imaging Centers
- Others
By Application
- Dermatology
- Uterine Fibroids
- Prostate Cancer
- Essential Tremor
- Breast Cancer
- Glaucoma
- Backpain, Facetogenic
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe High Intensity Focused Ultrasound Market by End Use
Chapter 5. Europe High Intensity Focused Ultrasound Market by Application
Chapter 6. Europe High Intensity Focused Ultrasound Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- EDAP TMS S.A
- Sonablate Corp.
- Verasonics, Inc.
- ALPINION MEDICAL SYSTEMS Co., Ltd.
- Theraclion
- Lynton Lasers Ltd
- ULTRAISER
- PROFOUND MEDICAL CORP.
Methodology
LOADING...
